Starling Oncology, Inc.
STLNW· Nasdaq
Released Aug 13, 2025, after the close
10-Q filed Aug 13, 2025, 44 days after period end · 0001628280-25-040225
| Metric | Q2 2025 | Q2 2024 | Q2 2023 | Q2 2022 |
|---|---|---|---|---|
| Revenue | $119.80M | $98.58M | $80.22M | $60.92M |
| Net Income | -$17.01M | -$15.48M | -$16.90M | -$5.45M |
| EPS Diluted |
Starling Oncology, Inc. · CIK 1799191 · Engraved from SEC EDGAR
| -$0.15 |
| -$0.17 |
| -$0.19 |
| -$0.06 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.